4-methylsulfonyl-substituted piperidine urea compounds

a technology of urea compounds and methylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfon

Active Publication Date: 2019-09-05
MYOKARDIA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a way to make certain types of drugs that can help reduce symptoms caused by heart disease. These drugs are given to people who have it's hardest to cure them effectively.

Problems solved by technology

This patent describes different types of heart conditions called DCM, which includes congestive heart failure and heart failure caused by various causes like infarcts, valve malfunctions, and certain inherited metabolism disorder syndrome. These conditions may result in reduced blood flow through the heart muscle causing fluid accumulation and impaired contractility. Different treatments exist depending on the specific type of heart condition being treated. However, current diagnostic tools are limited because they only provide overall assessment without distinguishing between different forms of heart damage. Therefore, it would be advantageoverforward to develop novel therapeutic agents and methods that could aid in better understanding and management of this condition.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 4-methylsulfonyl-substituted piperidine urea compounds
  • 4-methylsulfonyl-substituted piperidine urea compounds
  • 4-methylsulfonyl-substituted piperidine urea compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

on of 4-(((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)methyl)-N-(pyridin-4-yl)piperidine-1-carboxamide

[0072]

Compound 1.1. tert-Butyl 4-((tosyloxy)methyl)piperidine-1-carboxylate

[0073]A solution of tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (50 g, 232.25 mmol, 1.00 equiv), triethylamine (35.2 g, 347.86 mmol, 1.50 equiv), 4-dimethylaminopyridine (2.8 g, 22.92 mmol, 0.10 equiv) and 4-methylbenzene-1-sulfonyl chloride (53 g, 278.00 mmol, 1.20 equiv) in CH2Cl2 (500 mL) was stirred under argon overnight at room temperature. The solids were removed by filtration, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column (Ethyl Acetate / Petroleum ether=1 / 3 9 v / v)) to provide 78 g (91%) as a yellow solid. 1H-NMR (400 MHz, DMSO-d6): δ 7.78 (d, J=8.4 Hz, 2H), 7.48 (d, J=8.4 Hz, 2H), 3.87 (m, 4H), 2.49 (m, 2H), 2.42 (s, 3H), 1.76 (m, 1H), 1.53 (m, 2H), 1.36 (s, 9H), 0.96 (m, 2H) ppm.

Compound 1.2. tert-Butyl 4-((carbamimidoylthio)meth

example 2

on of N-(Pyridazin-4-yl)-4-(1-((4-(trifluoromethoxy)phenyl)sulfonyl)cyclopropyl)piperidine-1-carboxamide

[0080]

Compound 2.1. 4-(((4-(Trifluoromethoxy)phenyl)thio)methyl)pyridine

[0081]A solution of 4-(chloromethyl)pyridine (625 mg, 4.90 mmol, 1.00 equiv), K2CO3 (1.35 g, 9.70 mmol, 2.00 equiv) and 4-(trifluoromethoxy)benzene-1-thiol (950 mg, 4.89 mmol, 1.00 equiv) in DMF (10 mL) was stirred overnight at room temperature under argon, and the solids were removed by filtration. The filtrate was diluted with H2O (30 mL), and the resulting solution was extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (2×20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was purified on silica gel (EtOAc / petroleum ether) to provide 1.3 g (93%) of a light yellow oil.

Compound 2.2. 4-(((4-(Trifluoromethoxy)phenyl)sulfonyl)methyl)pyridine

[0082]A solution of 4-(((4-(trifluoromethoxy)phenyl)thio)methyl)pyridine (2.1, 800 mg,

example 3

on of 4-(((2-Cyano-4-(trifluoromethyl)phenyl)sulfonyl)-difluoromethyl)-N-(pyridazin-4-yl)piperidine-1-carboxamide

[0086]

Compound 3.1. S-(Pyridin-4-ylmethyl) ethanethioate

[0087]To a mixture of 4-(chloromethyl)pyridine hydrochloride (9 g, 54.87 mmol, 1.00 equiv) and K2CO3 (7.6 g, 54.99 mmol, 1.50 equiv) in DMF (50 mL) under argon was added potassium thioacetate (9.38 g, 82.13 mmol, 1.00 equiv) in several batches at 0° C. The resulting mixture was stirred for 1 h at 50° C. in an oil bath. After cooling to room temperature the reaction was quenched by the addition of ice water (500 mL). The resulting solution was extracted with EtOAc (3×300 mL). The combined organic layers were washed with brine (2×500 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to provide 9 g (98%) of a brown liquid. MS (ES, m / z): 168 [M+H]+.

Compound 3.2. 4-(((2-Bromo-4-(trifluoromethyl)phenyl)thio)methyl)pyridine

[0088]A mixture of S-(pyridin-4-ylmethyl) ethanethioate (3.1, 4.75 g,

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Capacitanceaaaaaaaaaa
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Login to view more

Abstract

The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner MYOKARDIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products